// App-Quantinova.ai

1886 : Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

Researchers

Presenter

  • E Michael Lewiecki

Principal Investigators

  • Rajani V Dinavahi

  • Marise Lazaretti-Castro

  • Peter R Ebeling

  • J Adachi

  • Akimitsu Miyauchi

  • Evelien Gielen

  • Cassandra E Milmont

  • Cesar Libanati

  • Andreas Grauer

Medical Centers

  • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM

  • Amgen Inc, Thousand Oaks, CA

  • Federal Univ. of Sao Paulo, Sao Paulo, Brazil.

  • Deakin University, Melbourne, Australia

  • McMaster University, Hamilton, ON, Canada

  • Miyauchi Medical Center, Osaka, Japan

  • UCB Pharma, Brussels, Belgium

Locations

  • United States

  • Brazil

  • Australia

  • Canada

  • Japan

  • Belgium

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Romosozumab

  • Denosumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved